Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is -7.85% lower on its value in year-to-date trading and has touched a low of $11.09 and a high of $18.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CPRX stock was last observed hovering at around $15.26 in the last trading session, with the day’s gains setting it 0.23%.
Currently trading at $15.49, the stock is -4.01% and 3.01% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.99 million and changing 1.51% at the moment leaves the stock 10.76% off its SMA200. CPRX registered -6.57% loss for a year compared to 6-month gain of 31.49%. The firm has a 50-day simple moving average (SMA 50) of $4.18 and a 200-day simple moving average (SMA200) of $13.91.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.19% loss in the last 1 month and extending the period to 3 months gives it a -9.47%, and is -1.65% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.58% over the week and 3.83% over the month.
Catalyst Pharmaceuticals Inc (CPRX) has around 167 employees, a market worth around $1.83B and $398.20M in sales. Current P/E ratio is 25.43 and Fwd P/E is 9.70. Profit margin for the company is 17.93%. Distance from 52-week low is 39.68% and -14.98% from its 52-week high. The company has generated returns on investments over the last 12 months (18.26%).
Catalyst Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0.24 with sales reaching $99.38M over the same period.The EPS is expected to grow by 88.36% this year, but quarterly earnings will post 16.40% year-over-year. Quarterly sales are estimated to grow 16.40% in year-over-year returns.
362 institutions hold shares in Catalyst Pharmaceuticals Inc (CPRX), with institutional investors hold 78.49% of the company’s shares. The shares outstanding are 107.12M, and float is at 99.87M with Short Float at 5.83%. Institutions hold 73.45% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 15.85 million shares valued at $213.05 million. The investor’s holdings represent 14.87% of the CPRX Shares outstanding. As of Jun 29, 2023, the second largest holder is State Street Corporation with 9.45 million shares valued at $127.05 million to account for 8.87% of the shares outstanding. The other top investors are Deerfield Management Company, L.P. (Series C) which holds 8.19 million shares representing 7.69% and valued at over $110.1 million, while Vanguard Group Inc holds 6.45% of the shares totaling 6.87 million with a market value of $92.36 million.
Catalyst Pharmaceuticals Inc (CPRX) Insider Activity
The most recent transaction is an insider sale by Elsbernd Brian, the company’s Chief Compliance/Legal Officer. SEC filings show that Elsbernd Brian sold 25,000 shares of the company’s common stock on Mar 27 ’24 at a price of $16.44 per share for a total of $0.41 million. Following the sale, the insider now owns 0.12 million shares.
Catalyst Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 15 ’23 that Harper Molly (Director) sold a total of 14,000 shares of the company’s common stock. The trade occurred on Dec 15 ’23 and was made at $14.39 per share for $0.2 million. Following the transaction, the insider now directly holds 0.0 shares of the CPRX stock.
Still, SEC filings show that on Dec 12 ’23, Tierney David S (Director) disposed off 50,000 shares at an average price of $13.32 for $0.67 million. The insider now directly holds 333,541 shares of Catalyst Pharmaceuticals Inc (CPRX).
